Science+Energy

Today in Science

Your Health

Teva Ends Hostile Bid for Mylan

Israeli drugmaker Teva Pharmaceuticals agreed to buy the generic-drug business of Allergan for about $40.5 billion in cash and stock, and ended its hostile bid for Mylan. Bloomberg Ed Hammond reports on "Bloomberg Markets." (Source: Bloomberg)